| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 29.64▼ | 29.64▼ | 29.59▼ | 29.67▼ | 28.48▲ |
| MA10 | 29.64▼ | 29.59▼ | 29.87▼ | 29.44▲ | 27.04▲ |
| MA20 | 29.65▼ | 29.93▼ | 29.91▼ | 28.71▲ | 24.36▲ |
| MA50 | 29.61▼ | 29.76▼ | 29.78▼ | 26.38▲ | 23.96▲ |
| MA100 | 29.80▼ | 29.68▼ | 29.39▲ | 24.07▲ | 21.54▲ |
| MA200 | 29.94▼ | 29.34▲ | 27.66▲ | 24.28▲ | 21.21▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.006▼ | -0.040▼ | -0.089▼ | -0.033▼ | 0.728▲ |
| RSI | 43.538▼ | 41.261▼ | 44.855▼ | 59.500▲ | 68.256▲ |
| STOCH | 52.381 | 58.912 | 20.516 | 60.725 | 80.565▲ |
| WILL %R | -100.000▼ | -79.286▼ | -80.272▼ | -45.104 | -13.516▲ |
| CCI | -48.892 | -11.448 | -63.612 | 56.170 | 127.159▲ |
|
Monday, August 24, 2026 05:42 PM
Acadia (ACAD) eyes Phase 2 remlifanserin Alzheimer’s psychosis results by September/October. Learn about the risks and revenue cushion from Daybue/Nuplazid.
|
|
Monday, August 24, 2026 12:01 AM
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 26/08/26 | 30.28 | 30.3799 | 29.28 | 29.58 | 1,336,040 |
| 25/08/26 | 29.99 | 30.76 | 29.845 | 30.57 | 1,522,423 |
| 24/08/26 | 29.28 | 29.77 | 29.145 | 29.65 | 866,874 |
| 21/08/26 | 29.08 | 29.615 | 28.80 | 29.50 | 1,067,488 |
| 20/08/26 | 30.00 | 30.00 | 28.95 | 29.04 | 1,318,667 |
| 19/08/26 | 30.66 | 30.96 | 30.07 | 30.21 | 2,221,998 |
| 18/08/26 | 29.14 | 30.25 | 29.05 | 30.18 | 2,020,549 |
| 17/08/26 | 28.63 | 29.03 | 28.21 | 29.01 | 1,071,255 |
| 14/08/26 | 28.26 | 28.425 | 27.9004 | 28.24 | 1,032,925 |
| 13/08/26 | 29.75 | 29.75 | 28.36 | 28.38 | 1,414,698 |
|
|
||||
|
|
||||
|
|